» Articles » PMID: 35310927

Long Noncoding RNAs As Promising Biomarkers in Cancer

Overview
Date 2022 Mar 21
PMID 35310927
Authors
Affiliations
Soon will be listed here.
Abstract

Despite many advances in diagnosis and therapy (surgery, radiation therapy, chemotherapy), cancer remains one of the most important public health problems worldwide. Every day, the role of exosomes in cancer development and metastasis is being better described. Liquid biopsy was developed for early detection of cancer through minimally invasive and serial examinations of body fluids, with the advantage of tracking tumor progression in real time. Exosomes are extracellular membrane vesicles with a diameter of 30-100 nm, which are secreted by various types of cells and are present in most biological fluids. For a long time, they were considered non-functional cellular components, and today it has already been proven that they are a means of intercellular information exchange. They can move bioactive molecules such as proteins, lipids, RNA and DNA. Several studies have shown that their contents, including proteins and noncoding nucleic acids, may be of particular interest as biomarkers of diseases. The vast majority of gene transcripts are actually characterized as noncoding RNAs (ncRNAs) and are clusters of RNAs that do not encode functional proteins. They can be small, about 20 nucleotides in length, and are known as microRNAs (miRNAs), or transcripts over 200 nucleotides in length, defined as long noncoding RNAs (lncRNAs). LncRNAs are a large group of ncRNAs over 200 nucleotides in length. LncRNAs, as regulatory factors, play an important role in complex cellular processes such as apoptosis, growth, differentiation, proliferation, etc. Recently, the results of many studies have also shown their essential role in carcinogenesis. Endogenous lncRNAs can be secreted by tumor cells into human biological fluids in the form of microvesicles, exosomes, or protein complexes, thereby forming circulating lncRNAs that are not degraded by RNA and are in a stable state. Aberrant expression of lncRNAs has been observed in cancer patients. In this context, endogenous lncRNAs can regulate the basic characteristics of cancer cells by controlling the expression of oncogenes associated with their suppressive and oncogenic functions. Therefore, circulating lncRNAs can be excellent biomarkers in cancer as well. This paper provides an overview of current research on the functional role of lncRNAs in cancer and their potential clinical applications as diagnostic biomarkers and therapeutic targets for cancer.

Citing Articles

Alterations in expression of miRNA 497 and long non-coding RNAS (XIST-TSIX) and its significant role in colorectal cancer prediction.

El-Magied M, Fawzy A, Mostafa M, Elnaggar G, Moselhy S, Elhady M Sci Rep. 2025; 15(1):7387.

PMID: 40032945 PMC: 11876683. DOI: 10.1038/s41598-025-90110-3.


The role of platelets in cancer: from their influence on tumor progression to their potential use in liquid biopsy.

Morales-Pacheco M, Valenzuela-Mayen M, Gonzalez-Alatriste A, Mendoza-Almanza G, Cortes-Ramirez S, Losada-Garcia A Biomark Res. 2025; 13(1):27.

PMID: 39934930 PMC: 11818056. DOI: 10.1186/s40364-025-00742-w.


Long Non-Coding RNAs in Malignant Human Brain Tumors: Driving Forces Behind Progression and Therapy.

Pei D, Zhang D, Guo Y, Chang H, Cui H Int J Mol Sci. 2025; 26(2).

PMID: 39859408 PMC: 11766336. DOI: 10.3390/ijms26020694.


Long non-coding RNAs as prognostic biomarkers in non-muscle invasive bladder cancer: A systematic review.

Hendri A, Suryawati S, Heriyanto D, Hardianti M, Pikatan N, Shaleh S Narra J. 2025; 4(3):e1233.

PMID: 39816119 PMC: 11731787. DOI: 10.52225/narra.v4i3.1233.


Exploring the role of noncoding RNAs in cancer diagnosis, prognosis, and precision medicine.

Eldakhakhny B, Sutaih A, Siddiqui M, Aqeeli Y, Awan A, Alsayegh M Noncoding RNA Res. 2025; 9(4):1315-1323.

PMID: 39764154 PMC: 11703603. DOI: 10.1016/j.ncrna.2024.06.015.


References
1.
Zhou R, Chen K, Zhang J, Xiao B, Huang Z, Ju C . The decade of exosomal long RNA species: an emerging cancer antagonist. Mol Cancer. 2018; 17(1):75. PMC: 5861621. DOI: 10.1186/s12943-018-0823-z. View

2.
Miao Y, Fan R, Chen L, Qian H . Clinical Significance of Long Non-coding RNA MALAT1 Expression in Tissue and Serum of Breast Cancer. Ann Clin Lab Sci. 2016; 46(4):418-24. View

3.
Lee Y . Carcinoembryonic antigen in patients with breast or colon cancer. West J Med. 1978; 129(5):374-80. PMC: 1238388. View

4.
Silva A, Bullock M, Calin G . The Clinical Relevance of Long Non-Coding RNAs in Cancer. Cancers (Basel). 2015; 7(4):2169-82. PMC: 4695884. DOI: 10.3390/cancers7040884. View

5.
Dong L, Lin W, Qi P, Xu M, Wu X, Ni S . Circulating Long RNAs in Serum Extracellular Vesicles: Their Characterization and Potential Application as Biomarkers for Diagnosis of Colorectal Cancer. Cancer Epidemiol Biomarkers Prev. 2016; 25(7):1158-66. DOI: 10.1158/1055-9965.EPI-16-0006. View